Compare AKA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKA | ANIX |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 108.5M |
| IPO Year | 2021 | 2013 |
| Metric | AKA | ANIX |
|---|---|---|
| Price | $10.78 | $3.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $24.33 | $8.67 |
| AVG Volume (30 Days) | 2.1K | ★ 312.4K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $210,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $8.42 | $2.32 |
| 52 Week High | $16.38 | $5.46 |
| Indicator | AKA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.64 |
| Support Level | N/A | $2.77 |
| Resistance Level | N/A | $4.52 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 95.31 |
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.